Oncolys Biopharma (4588.T) traded up 5.89 % during a 24 hours period ending at 01:04 AM Central Europe on Tuesday 27th. One Oncolys Biopharma stock can currently be bought for about JPY 6,300 on popular exchanges. Current supply of Oncolys Biopharma stocks is 29.5 mn. Oncolys Biopharma has a current market capitalization of JPY 174.9 bn and approximately JPY 5.1 bn worth of Oncolys Biopharma was traded on exchanges in the last 24 hours. Since last month end, Oncolys Biopharma has traded -1 % down. Simple moving average of last 200 days is at JPY 3,126.53. The highest price of past 52 weeks was recorded at JPY 7,020 on 10/06/2026. 52 weeks low was at JPY 668 on 10/30/2025.

Here is how related stocks have performed in the past 24 hours:

  • Create Sd (3148.T) traded up 0.63 % and now trades at JPY 3,260. Current market capitalisation for Create Sd is JPY 208 bn. Current price/earnings ratio for Create Sd is 12.43.

  • Hu (4544.T) traded flat 0 % and now trades at JPY 3,809. Hu has a market capitalisation of JPY 205.7 bn. Hu has a current price to earnings ratio of 21.72.

  • Shibaura Mechatronics (6590.T) traded down -1.88 % and now trades at JPY 3,020. Shibaura Mechatronics has a market capitalisation of JPY 205.5 bn. Current price/earnings ratio for Shibaura Mechatronics is 19.81.

  • Nittetsu Mining (1515.T) traded down -1.48 % and now trades at JPY 2,705. Nittetsu Mining has a market capitalisation of JPY 205.1 bn. Current price/earnings ratio for Nittetsu Mining is 13.37.

  • Ts Tech (7313.T) traded down -0.08 % and now trades at JPY 1,751. Current market capitalisation for Ts Tech is JPY 206.3 bn. Current price/earnings ratio for Ts Tech is 25.52.

About Oncolys Biopharma

Oncolys BioPharma Inc. is a health care biotechnology company based in Tokyo, Japan. The company specializes in conducting research, development, manufacturing, importing, and exporting oncolytic viruses, drugs, and tumor diagnostic agents. Their product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus in Phase I clinical stage for the treatment of esophageal cancer and hepatocellular carcinoma, as well as in Phase II clinical trial for the treatment of melanoma; OBP-801, a histone deacetylase inhibitor in Phase I clinical study for the treatment of solid tumors; and OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor in Phase II clinical trial for the treatment of HIV infection. Additionally, the company develops TelomeScan (OBP-401 and OBP-1101) for detecting living circulating tumor cells in blood from cancer patients. Oncolys BioPharma Inc. was founded in 2004 and is headquartered in Tokyo, Japan. Their website is www.oncolys.com , and they are listed on the Tokyo Stock Exchange. The IPO date was December 6, 2013.